519 related articles for article (PubMed ID: 33579739)
1. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
2. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).
Iwata H; Inoue K; Kaneko K; Ito Y; Tsugawa K; Hasegawa A; Nakagawa S; Kuratomi H; Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(12):1083-1091. PubMed ID: 31612909
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Kang C; Syed YY
Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
Mavratzas A; Seitz J; Smetanay K; Schneeweiss A; Jäger D; Fremd C
Future Oncol; 2020 Jan; 16(3):4439-4453. PubMed ID: 31829043
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Emens LA; Molinero L; Loi S; Rugo HS; Schneeweiss A; Diéras V; Iwata H; Barrios CH; Nechaeva M; Nguyen-Duc A; Chui SY; Husain A; Winer EP; Adams S; Schmid P
J Natl Cancer Inst; 2021 Aug; 113(8):1005-1016. PubMed ID: 33523233
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
Phua LC; Lee SC; Ng K; Abdul Aziz MI
BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
[TBL] [Abstract][Full Text] [Related]
11. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
Saji S; Ohsumi S; Ito M; Hayashi N; Kobayashi K; Masuda N; Niikura N; Yamashita T; Kiyama K; Hasegawa A; Nakagawa S; Hattori M
Jpn J Clin Oncol; 2022 Oct; 52(10):1124-1133. PubMed ID: 35750038
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
13. Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.
Otani Y; Mori K; Morikawa N; Mizutani M; Yasojima H; Masuyama M; Mano M; Masuda N
Immunotherapy; 2021 Feb; 13(3):189-194. PubMed ID: 33225795
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
15. Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.
Philipovskiy A; Chambers K; Konstantinidis I; McCallum R; Corral J; Gaur S
Immunotherapy; 2020 Dec; 12(18):1293-1302. PubMed ID: 32988260
[No Abstract] [Full Text] [Related]
16. Atezolizumab for the treatment of breast cancer.
Reddy SM; Carroll E; Nanda R
Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
[No Abstract] [Full Text] [Related]
17. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Emens LA; Adams S; Barrios CH; Diéras V; Iwata H; Loi S; Rugo HS; Schneeweiss A; Winer EP; Patel S; Henschel V; Swat A; Kaul M; Molinero L; Patel S; Chui SY; Schmid P
Ann Oncol; 2021 Aug; 32(8):983-993. PubMed ID: 34272041
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
Chisaki Y; Kuwada Y; Matsumura C; Yano Y
Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
[TBL] [Abstract][Full Text] [Related]
19. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK
BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316
[TBL] [Abstract][Full Text] [Related]
20. IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Cortés J; André F; Gonçalves A; Kümmel S; Martín M; Schmid P; Schuetz F; Swain SM; Easton V; Pollex E; Deurloo R; Dent R
Future Oncol; 2019 Jun; 15(17):1951-1961. PubMed ID: 30977385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
